Review



erk5 upstate  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc erk5 upstate
    Erk5 Upstate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 440 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erk5+upstate/Erk5+Antibody/pmc04333217-136-23-41
    Average 96 stars, based on 440 article reviews
    erk5 upstate - by Bioz Stars, 2026-09
    96/100 stars

    Images



    Similar Products

    90
    Upstate Biotechnology Inc erk5 upstate biotechnology #07-039 antibody
    Erk5 Upstate Biotechnology #07 039 Antibody, supplied by Upstate Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erk5+upstate/erk5+07+039+antibody/pm25388666-37-7-8
    Average 90 stars, based on 1 article reviews
    erk5 upstate biotechnology #07-039 antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc erk5 upstate
    Erk5 Upstate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erk5+upstate/Erk5+Antibody/pmc04333217-136-23-41
    Average 96 stars, based on 1 article reviews
    erk5 upstate - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    97
    Santa Cruz Biotechnology erk5 upstate
    Characterisation of cardiomyocyte-specific deletion of ERK2. (A) Quantitative real-time PCR analysis of mRNA levels of ERK2 in the left ventricle (LV), skeletal muscle (SM), brain, and liver. A 73% decrease in mRNA level was shown only in LV of ERK2 cko mice in comparison to ERK2 f/f mice. Data were derived from 3 independent experiments performed in triplicate and normalized to GAPDH content ( n = 3). (B) Immunoblot analysis confirmed specificity of ERK2 deletion in LV. ERK2 protein expression was comparable in various tissues. Tubulin served as protein loading control. The ratio of ERK2 expression to tubulin is shown in the bar graph. (C) Western blot analyses demonstrated unchanged activation and expression levels of ERK1 and MEK1/2. Expression of ERK3, ERK4, <t>ERK5,</t> p38 and JNK in ventricular extracts was the same in all genotypes. Tubulin served as protein loading control. (D) ERK1/2 kinase activity was examined on the tissue subjected to 1 week of TAC, demonstrating ERK1 activation did not compensate the loss of ERK2 in the heart ( n = 5). n.s.: no significant difference. Data presented as mean ± SEM.
    Erk5 Upstate, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/erk5+upstate/ERK+5+Antibody/pmc04046245-43-21-19
    Average 97 stars, based on 1 article reviews
    erk5 upstate - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    Image Search Results


    Characterisation of cardiomyocyte-specific deletion of ERK2. (A) Quantitative real-time PCR analysis of mRNA levels of ERK2 in the left ventricle (LV), skeletal muscle (SM), brain, and liver. A 73% decrease in mRNA level was shown only in LV of ERK2 cko mice in comparison to ERK2 f/f mice. Data were derived from 3 independent experiments performed in triplicate and normalized to GAPDH content ( n = 3). (B) Immunoblot analysis confirmed specificity of ERK2 deletion in LV. ERK2 protein expression was comparable in various tissues. Tubulin served as protein loading control. The ratio of ERK2 expression to tubulin is shown in the bar graph. (C) Western blot analyses demonstrated unchanged activation and expression levels of ERK1 and MEK1/2. Expression of ERK3, ERK4, ERK5, p38 and JNK in ventricular extracts was the same in all genotypes. Tubulin served as protein loading control. (D) ERK1/2 kinase activity was examined on the tissue subjected to 1 week of TAC, demonstrating ERK1 activation did not compensate the loss of ERK2 in the heart ( n = 5). n.s.: no significant difference. Data presented as mean ± SEM.

    Journal: Journal of Molecular and Cellular Cardiology

    Article Title: Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction

    doi: 10.1016/j.yjmcc.2014.03.002

    Figure Lengend Snippet: Characterisation of cardiomyocyte-specific deletion of ERK2. (A) Quantitative real-time PCR analysis of mRNA levels of ERK2 in the left ventricle (LV), skeletal muscle (SM), brain, and liver. A 73% decrease in mRNA level was shown only in LV of ERK2 cko mice in comparison to ERK2 f/f mice. Data were derived from 3 independent experiments performed in triplicate and normalized to GAPDH content ( n = 3). (B) Immunoblot analysis confirmed specificity of ERK2 deletion in LV. ERK2 protein expression was comparable in various tissues. Tubulin served as protein loading control. The ratio of ERK2 expression to tubulin is shown in the bar graph. (C) Western blot analyses demonstrated unchanged activation and expression levels of ERK1 and MEK1/2. Expression of ERK3, ERK4, ERK5, p38 and JNK in ventricular extracts was the same in all genotypes. Tubulin served as protein loading control. (D) ERK1/2 kinase activity was examined on the tissue subjected to 1 week of TAC, demonstrating ERK1 activation did not compensate the loss of ERK2 in the heart ( n = 5). n.s.: no significant difference. Data presented as mean ± SEM.

    Article Snippet: Protein extracts (30 μg) were subjected to Western blot analyses with the primary antibodies against ERK1 (Santa Cruz), ERK2 (Santa Cruz), ERK5 (Upstate), Phospho-ERK5 (Invitrogen), p38 (Santa Cruz), Phospho-ERK1/2, MEK1/2, Phospho-MEK1/2, Phospho-p38, JNK1/2, Phospho-JNK1/2, PKB, Phospho-PKB, active caspase 3 (Cell signaling) or α-Tubulin (Sigma-Aldrich).

    Techniques: Real-time Polymerase Chain Reaction, Derivative Assay, Western Blot, Expressing, Activation Assay, Activity Assay

    Analysis of hypertrophic regulators in ERK2 f/f and ERK2 cko ventricles. Protein extracts from ERK2 f/f and ERK2 cko ventricles after 1 week of sham or TAC operation were subjected to immunoblot analyses for total ERK2, ERK1, MEK1/2, PKB, p38, JNK and ERK5 expression as well as their phosphorylation levels using specific antibodies.

    Journal: Journal of Molecular and Cellular Cardiology

    Article Title: Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction

    doi: 10.1016/j.yjmcc.2014.03.002

    Figure Lengend Snippet: Analysis of hypertrophic regulators in ERK2 f/f and ERK2 cko ventricles. Protein extracts from ERK2 f/f and ERK2 cko ventricles after 1 week of sham or TAC operation were subjected to immunoblot analyses for total ERK2, ERK1, MEK1/2, PKB, p38, JNK and ERK5 expression as well as their phosphorylation levels using specific antibodies.

    Article Snippet: Protein extracts (30 μg) were subjected to Western blot analyses with the primary antibodies against ERK1 (Santa Cruz), ERK2 (Santa Cruz), ERK5 (Upstate), Phospho-ERK5 (Invitrogen), p38 (Santa Cruz), Phospho-ERK1/2, MEK1/2, Phospho-MEK1/2, Phospho-p38, JNK1/2, Phospho-JNK1/2, PKB, Phospho-PKB, active caspase 3 (Cell signaling) or α-Tubulin (Sigma-Aldrich).

    Techniques: Western Blot, Expressing